Background: Clinical trial evidence shows minimal survival gains and higher complication rates from radical prostatectomy (RP) versus watchful waiting (WW) for elderly men with localized prostate cancer (PCa). It is believed that these patients are overtreated. The current analyses aim to explore patient-level heterogeneity in survival effects, examine matching of patients to treatments in practice, and identify patient characteristics driving heterogenous effects, in order to present more comprehensive evidence about the concerns of overtreatment.
agnosed with prostate cancer (PCa); 80% of those diagnoses are for clinically localized cancer and a majority of patients receive aggressive treatments such as surgery or radiation therapy. 1 Herein, we focus on the comparative effectiveness evidence underlying a comparison of surgery with radical prostatectomy (RP) versus watchful waiting (WW) within 6 months of diagnosis of localized PCa among elderly patients and extensively explore the heterogeneity of these effects across patient characteristics in order to assess concerns that patients with PCa are overtreated during the first 6 months after diagnosis. 2, 3 Several randomized controlled trials and observational studies have compared surgery with observation for PCa. Before the era of prevalent prostate-specific antigen (PSA) screening, an 18-year-long Scandinavian trial found no significant difference between RP and WW in overall survival among the few elderly patients it had enrolled. 4 The 12-yearlong PIVOT trial, which enrolled localized PCa patients detected during the early era of PSA screening in the United States, found that RP was associated with a nonsignificant reduction in all-cause and PCa-specific mortality compared with observation among elderly men. 5 Hadley et al 6 studied the comparative effectiveness of RP versus WW in elderly patients using SEER-Medicare data with an instrumental variable (IV) approach and found results similar to the PIVOT trial. Xia et al 7 used microsimulation to demonstrate a 1.8-month increase in life expectancy for men treated with RP compared with active surveillance.
The summaries from these studies often distill comparisons down to a single number that represents the average incremental benefit or harm, and this simplified term is often presented or popularized in the media. 8 Despite evidence that substantial individual-level variability in PCa treatment effects may exist, 9 variability in survival effects remain underexplored. This variability is central to identifying patients at risk for overtreatment, which is defined primarily by the use of the aggressive therapies in the absence of survival benefits. 2, 10 In clinical trials, post hoc analyses of broad subgroups were conducted; however, these analyses were age adjusted, but they were rarely age stratified. 4, 5 We use a recently developed econometric methodology using IVs to address selection biases in observational studies and establish person-centered treatment (PeT) effects. 11 PeT effects estimate an average treatment effect for each person in the data, conditioning on their levels of risk factors, and accounting for the individualized distribution of unobserved heterogeneity. Consequently, such individualized effects can help study a variety of distributional questions on effectiveness such as examining the benefits and harms of RP versus WW.
METHODS

Data
Data for patients diagnosed with PCa between 1996 and 2002 were extracted from the SEER-Medicare linked dataset that includes data from 1995 to 2007 12, 13 along with patient zip codes of patients' residences. Everyone in the sample had at least 6 years' follow-up and many had followup through 12 years after diagnosis, although we capped follow-up at 11 years due to sample size issues. Various exclusions-in line with previous studies 6 -were applied as detailed in online-only Appendix (Table A1 , Supplemental Digital Content, http://links.lww.com/MLR/A819). We focused our analysis on the group of eligible patients aged 66-79 years at diagnosis.
Outcomes assessed included 11-year all-cause survival and 11-year PCa-specific survival. Date and cause of death data were obtained from SEER files. Comparison was made between RP without any form of radiation or hormone therapy in the first 6 months of diagnosis versus WW, defined as no use of surgery, hormone therapy, or radiation in the first 6 months of diagnosis along with at least 2 PSA tests within the first year after diagnosis.
An indicator of surgery is likely to be endogenous for 2 reasons: true severity of cancer is unobserved as we only have data on the cross-sectional characteristics of the tumor at diagnosis, but not how the tumor is growing or any associated change in PSA. Higher severity may be positively correlated with receipt of surgery and negatively correlated with survival. These correlations render the naive effects on surgery to be biased downward. Second, general frailties of the patients are unobserved, but would be negatively correlated with both receipt of surgery and survival, thereby generating an upward bias on the naive effect. Thus the net direction of bias remains ambiguous.
As the treatment indicator was subject to selection biases, we used an IV (denoted as Z) that was the hospital referral region (HRR)-specific rates (http://www.dartmou thatlas.org/data/region/) of WW among PCa patients in the year before the diagnosis of an index patient. 6 In addition, we adjusted for independent risk factors (X) that included clinical PCa stage and grade, 1 patient demographic characteristics, an indicator for metropolitan area, Elixhauser comorbidity indices based on hospitalization(s) in the year preceding diagnosis, year and state-fixed effects, and zipcode level area characteristics on racial makeup, population density, and education levels. We adjusted for other HRRlevel characteristics using logged versions of population size, and supply of hospital beds, physicians, specialists, and urologists per 100,000 patients.
Target Parameters to Explore Heterogenous Treatment Effects
In the presence of heterogeneity, a long line of statistical work has shown that traditional IV regressions tend to estimate a local average treatment effect parameter that is often not interpretable. 2, [14] [15] [16] Instead, we defined our primary target parameters to be the PeT effects. 2 For each person in the sample, a PeT effect is estimated, which is the treatment effect conditional on their observed risk factors and averaged over a distribution of unobserved confounders that is specific to this person as determined by his observed treatment choice. That is, if 80-year-old patients, on average, are less likely to choose surgery over WW and yet we observe an 80year-old patient to choose surgery, it tells us something about this patient's unobserved risk factor levels. Thus exploiting a choice model and a continuous IV, we are able to precisely identify a PeT effect for each individual in our sample. A brief description of this parameter is provided here. More intuitive explanation of this treatment effect parameter is provided in the online-only Appendix (Supplemental Digital Content, http://links.lww.com/MLR/A819).
To overcome the problems of interpreting traditional IV estimators, the concept of the marginal treatment effect (MTE) was developed (http://www.dartmouthatlas.org/data/ region/). 13, 14 MTE identifies an effect for an individual who is at the margin of choice and is defined to be conditional on observed levels of X and also a specific level of the normed unobserved confounders (U) that makes a person indifferent to choosing between 2 treatments (http://www.dartmou thatlas.org/data/region/). 13, 14 A local IV (LIV) estimator for MTE is given by the partial derivative of the outcomes, Y, with respect to the estimated propensity to receive treatment PðX ; ZÞ.
PeT effects can then be computed by aggregating MTE(x,u) over respective distribution of U that corresponds to an individual's treatment choice given everything else. 2 The PeT effects provide truly individualized estimates of treatment effects for identifiable individuals in our data. PeT effects can be easily aggregated to form meaningful treatment effect parameters, such as the average treatment effect. An extensive discussion on the definition and identification of these effects are provided in the online-only Appendix (Supplemental Digital Content, http://links.lww.com/MLR/ A819).
Statistical Analysis
To explore the validity of the IV, we ran a logistic model for RP with only the IV as a regressor. We then compared the imbalance in patient-level independent risk factors across treatment categories with their imbalance across the median of the IV-only predicted propensity to choose RP. A valid IV would necessarily reduce such imbalances. To illustrate the imbalances for all covariates across treatment choices and across IV median in the same figure, we standardized each covariate by demeaning and dividing by its SD to form a Z-score. Levels of these Z-scores are then compared across treatment choices and across median of the IV. Finally, we assessed the strength of the IV in a logistic model for RP along with all other independent risk factors.
A LIV Estimator for Survival Outcomes
An LIV estimator was implemented using a discretetime hazard formulation where each observation represented a person-month and a binary indicator, D k , took on a value of zero in each month (k) through the end of follow-up unless the end of follow-up was when the person died and the indicator value turned to 1. Such a model does not enforce a proportional hazard assumption. By construction, E(D k ) = h k = hazard of death in month k and was modeled as:
where g() is a control function that is specified using main effects ofP; X and k interactions ofP with X and k, and polynomial ofP up to a degree that shows statistical significance using likelihood ratio tests. Extensive sensitivity analyses were performed on the functional form of the LIV estimand. The methods to compute the MTEs on cumulative survival are shown in the online-only Appendix (Supplemental Digital Content, http://links.lww.com/MLR/A819). PeT estimates are then derived based on conditional aggregation of the MTE estimates. 2 One thousand clustered bootstrap replicates of the data were used to estimate SEs for mean treatment effects and also individual-level PeT effects.
We evaluated the average counterfactual survival curves (ie, the average survival curve if all patients had chosen a treatment) under RP and WW by adding or subtracting the average estimated PeT effects on month-specific cumulative survival probabilities to the observed survival probabilities depending on treatment choices. We also calculated the expected incremental survival in months by adding the PeT effects on month-specific cumulative survival probabilities over all 132 months. We studied the average effects by treatment receipt and a variety of subgroups including age, race, tumor grade, and tumor stage subgroups. We examined the correlation between the individual effects on overall and PCa-specific survival. We also tested the hypothesis of "passive personalization," which states that providers in practice may already personalize treatments to patients on specific outcome dimensions and thus patients receiving surgery may, on average, have higher incremental survival benefits than a random person drawn from this population. 17, 18 We aim to establish a doseresponse relationship where patients expected to get larger survival benefits from surgery are more likely to receive surgery.
Finally, as PeT effects are derived on the basis of a nonlinear control function that allows for complex interactions across all risk factors, we develop a simple predictive index using the estimated PeT effects as outcomes and studying whether certain combinations of patient characteristics may be predictive of individualized effects favoring RP over WW. We randomly split the estimated PeTs 80:20, trained an index to predict patients who were expected to gain at least a certain number of months of PCa-specific survival with RP over WW, and validated the index in the 20% holdout sample. Note that this process helps in preventing overfitting of the predictive index to the data, but does not provide true external validation of the predictions.
RESULTS
Characteristics of the Sample Patients
Our final analytic sample consists of 11,036 patients, of whom 8462 (77%) underwent RP. RP patients were significantly younger and had a higher proportion of clinical T1 PCa and high-grade tumors ( Table 1 ). Both groups of patients had the same average number of comorbidities identified during the year before diagnosis (84% had at least 1 comorbidity; on average, each patient had 2.2 comorbidities). However, the composition of comorbidities varied-RP patients had significantly lower rates of congestive heart failure, peripheral vascular disease, and diabetes, but higher rates of chronic lung disease, obesity, fluid and electrolyte disorders, and deficiency anemias.
The IV was found to be strongly predictive of receipt of RP conditional on other factors (F-stat: 14.2, P < 0.0001). The Z-scores show larger spread across treatment choices than across IV median implying that IV is able to reduce imbalance in these covariates (Fig. 1 ). The outcomes models (ie, control functions) satisfied all residual-base goodness-offit tests. The results presented below were robust to alternative formulations of LIV estimands
All-Cause Mortality
By the end of 2007, 2687 (24%) men had died, including 1930 (23%) men who underwent RP and 757 (29%) men on WW. PeT analyses reveal that the average incremental effect of RP over WW on 11-year overall survival is 1.1 months (95% CI, À 25, 28; P = 0.94). The average counterfactual survival months over 11 years is 104.9 months (95% CI, 92.3, 117.5) had all patients received RP and 103.8 months (95% CI, 81.9, 125.7) had all patients undergone WW. The average absolute increase in survival with RP is not significant at any time interval but shows slight improvement after 6 years ( Fig. 2A; 2 .7% increase; 95% CI, À 25%, 45%; P = 0.88).
with 107 of 2574 (4.2%) men on WW. On the basis of the PeT analyses, we find that that the average incremental effect of RP over WW on 11-year PCa-specific survival is 1.7 months (95% CI, À 25, 29; P = 0.90). The absolute estimated survival with RP was identical to that with WW throughout the 11-year study period (Fig. 2B ). After 11 years, RP was associated with a nonsignificant average absolute increase in survival of 0.6% (95% CI, À 30.4, 31.6; P = 0.96). Covariate imbalance across treatments versus across instrumental variable (IV). Each covariate is standardized by demeaning and dividing by its SD to form a Z-score. Levels of these Z-scores are then compared across treatment choices and across median of the IV. The Z-scores show larger spread across treatment choices than across IV median implying that IV is able to reduce imbalance in these covariates.
Heterogeneity and Subgroup Analyses
The all-cause or PCa-specific survival effects did not differ significantly according to age, race, grade, or stage (Figs. 2C, D) . However, each of these subgroups explained only a small fraction of the total variation in individual-level treatment effects (0%-9%). Figure 3A illustrates the full distribution of individual treatment effects across the survival outcomes. Each dot in this figure is a patient, corresponding to his PeT effect on PCa survival on the x-axis and his overall survival on the y-axis. There was a strong positive correlation between the all-cause and PCa-specific survival effects (correlation coefficient: 0.33; 95% CI, 0.03, 0.53). Only 0.67% of patients had significant positive PCa-specific survival effects of RP over WW at the 10% level. Among these patients, the 11-year PCa-specific survival effects ranged from 15 to 122 months indicating that there were some patients who could presumably get substantial survival benefits from RP but they constituted a small fraction of the PCa population. Overall, about 6% of patients were expected to get at least 15 months of PCa-specific benefits from RP over WW.
Selection in Practice
The average survival effects among those who received RP were larger than those who received WW. For allcause survival, the average effect among those who received RP was 2.0 months (95% CI, À 26, 30) and for WW recipients was À 1.8 months (95% CI, À 24, 21); the difference of 3.8 months was not significant (95% CI, À 3.0, 17.0). For PCa-specific survival, the average effect among those who received RP was 2.8 months (95% CI, À 28, 34) and for WW recipients was À 2.1 months (95% CI, À 22, 18); the difference of 4.9 months was not significant (95% CI, À 6.0, 42.0). However, in both cases, those who received RP were likely to benefit more from RP than those who received WW.
This positive self-selection is further illustrated in Figure 3B -patients who received RP were less likely to get negative survival effects from RP compared with those who received WW. Therefore, patients undergoing RP exhibited greater clustering in the right upper quadrant of Figure 3B , whereas those receiving WW clustered in the left lower quadrant. Figures 3C, D illustrate the rate of RP use among patients with different levels of expected allcause ( Fig. 3C) and PCa-specific ( Fig. 3D ) survival effects of RP over WW. Overall, it is observed that groups of patients with higher expected survival benefits from RP over WW are more likely to get RP. Compared with all-cause survival, the selection of RP in practice seems to be driven mostly by PCaspecific survival. Patients expected to attain 15 months of PCa-specific survival gains from RP over WW almost always received RP. In comparison, the rate of RP use among those who were significantly hurt by RP was much lower.
Identifying Patients Likely to Benefit From RP
The characteristics strongly associated (P < 0.001) with PCa-specific survival benefits of at least 15 months (B6%) with RP over WW are shown in Table 2 . The factors iden-tified have strong face validity based on the conceptual expectations and associations established in the literature. [19] [20] [21] Our final predictive index achieved high ROC characteristics in the split-sample analysis (out-of-sample AUC: 0.89; 95% CI, 0.88, 0.91).
DISCUSSION
We used novel IV analysis to address unmeasured confounders in observational data and also to estimate PeT effects and understand the individual variability in the survival benefit of surgery versus WW for men with clinically localized PCa. Given the study timeframe, the length of patient follow-up, and the difficulty identifying active surveillance with claims data, our cohort and study results compare favorably with PIVOT, 22 where the nonoperative patients were not managed with active surveillance; rather, PIVOT patients in the observation arm were managed expectantly, without protocol prostate needle biopsies to evaluate for reclassification of their cancers. The SEER-Medicare patients in our study were diagnosed be-tween1996 and 2002 compared with 1994-2002 for PIVOT. Unlike PIVOT, however, our cases derive from populationbased data, and may be more generalizable.
Our study corroborated several recent analyses thatin a screen-detected population-aggressive intervention for localized PCa has minimal benefit on survival compared with conservative management with WW. In addition, while exploring individual-level heterogeneity in effects, we found that although some patients could presumably get significant survival benefits from RP over WW, they constitute a small fraction of the population, thereby supporting concerns that the contemporary PCa population may be overtreated. Individual characteristics that were associated with benefit from WW rather than aggressive intervention with RP included a history of recent hospitalization and specific comorbid conditions such as congestive heart failure and valvular heart disease, diabetes, obesity, and depression. Because these individual characteristics are often clustered, our next steps include characterizing projected survival benefits of PCa treatment based on clustered profiles of patient characteristics such as combinations of linked comorbidities, which would align with the movement toward patient-centered outcomes research. 23 This clustering of comorbid conditions may explain counterintuitive findings such as projected benefit to RP for patients with complicated diabetes, but projected benefit to WW for patients with uncomplicated diabetes. Our results corroborate findings from Daskivich et al, 24 that men with greater comorbidity are often treated despite minimal expected benefit from aggressive intervention for their PCa.
In practice, patients who are more likely to benefit seem to be triaged into aggressive treatment; however, the selection by providers is not accurate. Figure 3 supports that PCa-specific survival drives selection for treatment rather than overall survival. Thus, providers may focus on cancerspecific risk factors such as Gleason score and PSA, and be less inclusive of factors that may belie patient risk for competing causes of mortality into their treatment decision making. This further supports development of tools such as a predictive personalized calculator, which would aid clinicians in understanding which patients are likely to benefit from consideration of aggressive treatment. For example, a recent published nomogram is a step in the right direction, 25 but only classifies patients by cancer characteristics and not their varying comorbid disease burden.
Our study has several limitations. SEER-Medicare data are observational in nature and therefore observed treatment choices are always subject to selection biases, which we have addressed through IV analysis. We analyzed cancer-specific and overall survival outcomes for a cohort of men diagnosed with PCa over 10 years ago. However, this allowed ascertainment of long-term survival outcomes that are critical in conducting comparative effectiveness research in PCa care, given the indolence of even high-risk PCa. 26 The SEER data did not include PSA, limiting our ability to accurately project PCa risk category. Evaluation of more contemporary data, as that data matures and long-term outcomes are available, would allow for more specificity in assignment of risk of cancer progression and cancerspecific mortality at the time of PCa diagnosis.
Moreover, we wanted to focus on the comparative question of RP versus WW in line with the clinical trial evidence on this question. However, this means that we have dropped patients who received radiation therapy in practice, in line with the previous analyses. 6 This implies that the estimated average effects between RP and WW only extend to the population of patients who are at a point of equipoise between RP and WW.
The PeT effects estimated using LIV methods is a powerful way to explore treatment effect heterogeneity. The typical assumptions of an IV analyses apply to such estimation. In addition, one must have at least 1 continuous IV that is strong enough to produce a near-full support in the estimated propensity scores (in our case 0.12-0.98) to explore the MTEs across all the margins of choices. Lastly, proper care should be devoted in developing the control function so that the relationship between outcomes and the estimated propensity scores are not misspecified. We explore a variety of goodness-of-fit tests to detect such misspecifications.
Despite these challenges, we demonstrated that the majority of individuals in this screened population derive minimal long-term survival benefit from RP over WW, confirming concerns of PCa overtreatment. We identified a set of patient characteristics that could help identify the small fraction who would benefit from RP, which might inform a personalized decision support calculator. Implementation of such a tool in practice might increase consideration of Reference group is highly less likely to obtain prostate cancer-specific survival benefits from prostatectomy versus watchful waiting. observational management strategies such as active surveillance and decrease overtreatment of localized PCa.
